• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HIV-1 gp41的HR1区域中的L33M突变可能在T20耐药性中起作用。

Mutation L33M in the HR1 region of HIV-1 gp41 may play a role in T20 resistance.

作者信息

Chong Huihui, Xu Sihong, Zhang Chuntao, Nie Jianhui, Wang Youchun

机构信息

Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

J Clin Virol. 2009 Jul;45(3):255-8. doi: 10.1016/j.jcv.2009.05.001. Epub 2009 May 31.

DOI:10.1016/j.jcv.2009.05.001
PMID:19487156
Abstract

BACKGROUND

Although Enfuvirtide (T20) has not been used in China, investigating the natural occurrence of primary resistance mutations in the HR1 region of the gp41 sequence from T20 naïve patients would help in determining treatment strategies for AIDS patients.

OBJECTIVES

To investigate natural mutations in the HR1 region of the gp41 sequence in China and evaluate their biological function.

STUDY DESIGN

The amino acid sequences in the HR1 region of 27 isolates including subtypes AE, BC and B' from Chinese T20 naïve patients were analyzed. All 27 isolates were constructed into pseudoviruses and their susceptibility to T20 was measured by using recombinant virus assays.

RESULTS

Mutations in a 10 amino acid motif, such as N42S and N42R, and those outside this motif, such as L33M, R46S, A50V, Q52H and L54M, were found in the 27 isolates. N in position 42 was mutated to S in all three AE subtype strains and 17 of 18 subtype BC strains, whilst it was mutated to R in all 6 subtypes B strains. Compared to the SF162 strain, the susceptibility of the mutants, except for L33M, to T20 was not significantly different. After L was mutated to M in position 33 of six strains by site directed mutagenesis, their IC50 values were increased by 3.7-7.9-fold.

CONCLUSIONS

Mutations outside a 10 amino acid motif in HR1, such as L33M, may cause T20 resistance.

摘要

背景

尽管恩夫韦肽(T20)尚未在中国使用,但研究初治患者gp41序列HR1区原发性耐药突变的自然发生情况将有助于确定艾滋病患者的治疗策略。

目的

研究中国患者gp41序列HR1区的自然突变并评估其生物学功能。

研究设计

分析了来自中国初治患者的27株病毒株(包括AE、BC和B'亚型)gp41序列HR1区的氨基酸序列。将所有27株病毒株构建成假病毒,并通过重组病毒试验测定其对T20的敏感性。

结果

在27株病毒株中发现了10个氨基酸基序内的突变,如N42S和N42R,以及该基序外的突变,如L33M、R46S、A50V、Q52H和L54M。在所有3株AE亚型毒株和18株BC亚型毒株中的17株中,42位的N突变为S,而在所有6株B亚型毒株中,42位的N突变为R。与SF162毒株相比,除L33M外,其他突变体对T20的敏感性无显著差异。通过定点诱变使6株毒株33位的L突变为M后,其半数抑制浓度(IC50)值增加了3.7至7.9倍。

结论

HR1区10个氨基酸基序外的突变,如L33M,可能导致对T20耐药。

相似文献

1
Mutation L33M in the HR1 region of HIV-1 gp41 may play a role in T20 resistance.HIV-1 gp41的HR1区域中的L33M突变可能在T20耐药性中起作用。
J Clin Virol. 2009 Jul;45(3):255-8. doi: 10.1016/j.jcv.2009.05.001. Epub 2009 May 31.
2
Natural resistance-associated mutations to Enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients.初治患者中针对恩夫韦肽(T20)的天然耐药相关突变以及不同HIV-1基因亚型gp41区域的多态性
J Clin Virol. 2005 Mar;32(3):248-53. doi: 10.1016/j.jcv.2004.11.009.
3
Evolution of genotypic resistance to enfuvirtide in HIV-1 isolates from different group M subtypes.不同M组亚型的HIV-1分离株中对恩夫韦肽的基因型耐药性演变。
J Clin Virol. 2009 Apr;44(4):325-8. doi: 10.1016/j.jcv.2009.01.012. Epub 2009 Feb 23.
4
High prevalence of primary Enfuvirtide (ENF) resistance-associated mutations in HIV-1-infected patients in Hong Kong.香港 HIV-1 感染患者中原发性恩夫韦肽(ENF)耐药相关突变的高流行率。
J Clin Virol. 2010 Mar;47(3):273-5. doi: 10.1016/j.jcv.2010.01.002. Epub 2010 Jan 29.
5
Human immunodeficiency virus type 1 gp 41 mutations in proviral DNA among antiretroviral treatment-naive individuals from India.来自印度的未接受过抗逆转录病毒治疗个体的前病毒DNA中1型人类免疫缺陷病毒gp 41突变
AIDS Res Hum Retroviruses. 2009 May;25(5):521-3. doi: 10.1089/aid.2008.0244.
6
Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.经长期恩夫韦肽治疗在体内选择的HIV-1毒株的耐药性和复制能力。
New Microbiol. 2004 Apr;27(2 Suppl 1):51-61.
7
Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1.对感染HIV-1的接受治疗患者的T20基因型和表型耐药性进行长期监测。
J Med Virol. 2006 Feb;78(2):141-7. doi: 10.1002/jmv.20520.
8
Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC.B、C 和 CRF31_BC 亚型中 HIV-1 进入抑制剂的天然耐药突变。
J Clin Virol. 2012 May;54(1):6-10. doi: 10.1016/j.jcv.2012.01.005. Epub 2012 Feb 13.
9
Enfuvirtide (T-20) resistance-related mutations in HIV type 1 subtypes B, C, and F isolates from Brazilian patients failing HAART.来自巴西接受高效抗逆转录病毒治疗(HAART)失败患者的1型艾滋病毒B、C和F亚型分离株中的恩夫韦肽(T - 20)耐药相关突变。
AIDS Res Hum Retroviruses. 2009 Feb;25(2):193-8. doi: 10.1089/aid.2008.0160.
10
Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.七肽重复序列2突变增强了对恩夫韦肽耐药的HIV-1 gp41发夹结构的稳定性。
Antivir Ther. 2005;10(8):893-900.

引用本文的文献

1
HIV-1 pseudoviruses constructed in China regulatory laboratory.中国监管实验室构建的 HIV-1 假病毒。
Emerg Microbes Infect. 2019 Dec 20;9(1):32-41. doi: 10.1080/22221751.2019.1702479. eCollection 2020.
2
Assessment of Antibody Interference of Enfuvirtide (T20) Function Shows Assay Dependent Variability.恩夫韦肽(T20)功能的抗体干扰评估显示检测结果存在依赖性变异性。
Curr HIV Res. 2018;16(6):404-415. doi: 10.2174/1570162X17666190228154850.
3
Current status on the development of pseudoviruses for enveloped viruses.包膜病毒假病毒的研究进展。
Rev Med Virol. 2018 Jan;28(1). doi: 10.1002/rmv.1963. Epub 2017 Dec 7.
4
DNA Triplex-Based Complexes Display Anti-HIV-1-Cell Fusion Activity.基于DNA三链体的复合物具有抗HIV-1细胞融合活性。
Nucleic Acid Ther. 2015 Aug;25(4):219-25. doi: 10.1089/nat.2015.0535.
5
Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.HIV-1对靶向Gp41口袋的短肽融合抑制剂的耐药机制
J Virol. 2015 Jun;89(11):5801-11. doi: 10.1128/JVI.00373-15. Epub 2015 Mar 18.
6
DNA duplexes with hydrophobic modifications inhibit fusion between HIV-1 and cell membranes.带有疏水性修饰的 DNA 双链体抑制 HIV-1 与细胞膜融合。
Antimicrob Agents Chemother. 2013 Oct;57(10):4963-70. doi: 10.1128/AAC.00758-13. Epub 2013 Jul 29.
7
Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652.通过对 HIV-1 融合抑制剂 CP621-652 的结构深入了解,发现了病毒进入和抑制的关键残基。
J Biol Chem. 2012 Jun 8;287(24):20281-9. doi: 10.1074/jbc.M112.354126. Epub 2012 Apr 16.
8
Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.3-马来酰亚胺基丙基磺酸酯修饰的肽融合抑制剂 albuvirtide 的生物物理特性和广谱抗 HIV 活性。
PLoS One. 2012;7(3):e32599. doi: 10.1371/journal.pone.0032599. Epub 2012 Mar 5.